CC-1

PSMAxCD3 bispecific antibody

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for CC-1, covering 2024-05-16 to 2025-04-23. Get the full timeline:

Most recent: Clinical Trial Update: Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung [Phase 1, Phase 2]